GET DAILY SIGNALSWhy Is Xeris Biopharma Holdings (XERS) Stock Up +13.53% Today?
Key Takeaways
- XERS climbed 13.53% in Friday's session, extending a powerful post-earnings rally.
- The primary catalyst is follow-through buying after blowout third-quarter results reported after Thursday's close, headlined by 44% revenue growth.
- Secondary drivers include sharply raised full-year and long-term revenue guidance, accelerating Recorlev sales, and a wave of analyst price-target increases.
- The move is outpacing the broader market and biotech peers, reflecting a company-specific growth re-rating rather than sector-wide momentum.
- Traders are watching whether shares can hold above the earnings gap and technical breakout levels in the sessions ahead.
- For more detail on this ticker's Price Targets, Earnings, and Forecast, explore the dedicated pages on Tickeron.
- Discover which AI-powered strategies are performing best right now by exploring Trending AI Robots.
Opening Summary
XERS — Xeris Biopharma Holdings, Inc., a specialty pharmaceutical company developing and commercializing therapies for endocrinology and rare diseases — extended its rally on Friday, rising 13.53% to $14.85 from a prior close of $13.08. The gain builds on Thursday's roughly 25% surge following stronger-than-expected third-quarter results, with markets citing sustained investor enthusiasm over accelerating demand for the company's Cushing's syndrome treatment, Recorlev, upgraded financial guidance, and a string of bullish analyst revisions.
Earnings Results and Raised Guidance
The dominant catalyst remains the company's third-quarter report, released after Thursday's close. XERS posted revenue of $107.2 million, up 44% year over year and comfortably ahead of the roughly $101.7 million analysts had expected. Earnings per share of $0.06 beat consensus estimates of around $0.02 to $0.03, marking a dramatic swing from break-even results a year earlier.
Equally important, management raised its full-year 2026 revenue outlook to a range of $395 million to $405 million, up from a prior range of $385 million to $390 million. The company also lifted its long-term target, now projecting more than $1 billion in total revenue by 2030 versus an earlier forecast of roughly $750 million. Chief Executive John Shannon said the results put the company "on a new growth curve."
Recorlev Momentum
At the center of the growth story is Recorlev, the company's oral therapy for endogenous Cushing's syndrome. Recorlev sales surged 93% year over year to approximately $71.5 million, well above analyst projections. Shannon indicated that Recorlev is now on a path to approach $1 billion in annual net revenue three to four years earlier than previously expected — a key detail that reshaped the company's long-term valuation narrative and fueled the extended rally. The gains in Recorlev more than offset a year-over-year decline in Gvoke, the company's severe hypoglycemia treatment, which management attributed in part to a one-time accounting adjustment.
Analyst Upgrades and Price-Target Raises
A wave of post-earnings analyst action added fuel to the move. H.C. Wainwright raised its price target to $18 from $10 while maintaining a Buy rating, citing a materially stronger growth outlook for the commercial business. Piper Sandler lifted its target to $12 from $8, while other firms — including Barclays, which previously raised its target to $14 from $12 with an Overweight rating — have also revised estimates higher. The consensus rating on the shares remains favorable, reflecting renewed confidence in the company's commercial trajectory.
Market Context and Trading Activity
The share price surge has been accompanied by a sharp increase in trading volume. Thursday's session saw more than 7 million shares change hands, several times the company's typical daily volume, as the stock gapped up from a prior close near $10.46 and touched a 52-week high above $13.74. Friday's follow-through has kept XERS trading near multi-year highs, well above its 50-day and 200-day moving averages, a technical posture that signals sustained momentum. The move is company-specific: it has dramatically outpaced the broader equity market and most specialty-pharmaceutical peers, which have not posted comparable gains during the same period.
What Comes Next for XERS
Investors will now watch whether XERS can consolidate its gains and hold above the post-earnings gap, a level technical analysts view as key support. Attention will turn to the company's next quarterly report and any further updates on Recorlev's launch trajectory, as well as progress on its pipeline, including the Phase 3 program for XP-8121, a once-weekly hypothyroidism injection expected to begin its Cornerstone trial by the end of 2026. Risks include the stock's richer valuation following the rapid re-rating, dependence on a limited number of products, and the possibility that commercial momentum or pipeline timelines fall short of newly elevated expectations.
Trending AI Robots
Tickeron offers hundreds of AI-powered trading bots covering thousands of tickers, each with its own strategy, timeframe, performance metrics, and traded symbols. Only the strongest performers under current market conditions are featured in the curated Trending AI Robots section, giving traders a focused view of strategies that are working right now. Explore the page to see which AI-driven approaches are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for XERS turns positive, indicating new upward trend
XERS saw its Momentum Indicator move above the 0 level on November 05, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 83 similar instances where the indicator turned positive. In 72 of the 83 cases, the stock moved higher in the following days. The odds of a move higher are at 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for XERS just turned positive on November 05, 2026. Looking at past instances where XERS's MACD turned positive, the stock continued to rise in 36 of 42 cases over the following month. The odds of a continued upward trend are 86%.
Following a +45.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where XERS advanced for three days, in 222 of 258 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
The Aroon Indicator entered an Uptrend today. In 189 of 232 cases where XERS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XERS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
XERS broke above its upper Bollinger Band on November 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: XERS's P/B Ratio (-284.700) is very low in comparison to the industry average of (7.254). XERS has a moderately low P/E Ratio (-152.000) as compared to the industry average of (0.575). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.061) among similar stocks. P/S Ratio (4.196) is also within normal values, averaging (181.047).
The Tickeron Profit vs. Risk Rating rating for this company is 8 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. XERS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
What is Insurance and Why is it Essential for Financial Stability?
What does “Buy the Dips” Mean?
What is Supply Chain Management(SCM) and Why is it Crucial for Modern Businesses?
What is the definition of Gap Insurance?
What Are the Different Types of Economies and How Do They Influence Global Dynamics?
General Information
a developer of ready-to-use, liquid-stable injectables
Industry PharmaceuticalsGeneric
Advertisement